AASLD 2026 会议报道:肝细胞癌监测改善生存,粪菌移植联合仑伐替尼试验未见显著获益
AASLD 2026 | 肝癌第二弹:粪菌移植没能救晚期肝癌,一次超声却多给了18个月
一项巴西前瞻性队列研究显示,结构化肝细胞癌监测与总生存期延长相关(48.
2026年11月5日-9日,全球肝病领域顶级学术盛会-The Liver Meeting 2026 (AASLD 2026)在美国•丹佛召开。本届大会汇聚来自世界各地的肝病临床专家与基础研究学者,围绕病毒性肝炎、代谢功能障碍相关脂肪性肝病、肝硬化及其并发症、肝癌、肝移植和肝病基础研究等领域,集中展示前沿研究成果与临床诊疗新进展。
为助力广大读者精准捕捉会议的学术精髓,及时洞悉领域前沿动态,肝胆相照平台特别甄选会议摘要中的热点研究内容,本篇专题报道将聚焦“肝细胞癌”这一关键领域,为广大同仁提供最新研究进展,展望其在临床实践中的广阔应用前景。
一 摘要编号:4262
肝细胞癌监测对生存率的真实世界影响:一项巴西前瞻性队列研究
REAL-WORLD IMPACT OF HEPATOCELLULAR CARCINOMA SURVEILLANCE ON SURVIVAL: A PROSPECTIVE BRAZILIAN COHORT
作者:Diego Vieira1 Rodrigo Cambraia1 Geraldo Pereira1 Lucy Ana Fonseca1 Marcelo Chaves França1 Rosangela Teixeira1
1 Hospital das Clínicas (EBSERH/ UFMG), School of Medicine, Federal University of Minas Gerais
背景
指南建议对肝硬化患者及部分其他高风险人群开展肝细胞癌(HCC)监测,以期实现早期检出、改善患者预后。但在真实世界场景下,有关监测对肿瘤负荷、肝储备功能及总生存期(OS)影响的证据仍然有限。本研究旨在评估结构化HCC监测与肝硬化合并HCC患者的肿瘤分期、肝储备功能及总生存之间的关联。
Background:Hepatocellular carcinoma (HCC) surveillance is recommended for patients with cirrhosis and selected high-risk populations, playing a pivotal role in early tumor detection and improved outcomes. However, evidence regarding the real-world impact of surveillance on tumor burden, hepatic reserve, and overall survival (OS) remains limited. This study evaluated the effect of structured HCC surveillance on tumor stage, hepatic reserve, and OS in cirrhosis associated HCC patients.
方法
2019-2024年,本研究在一家三级HCC转诊中心前瞻性纳入患者;所有HCC均依据LI-RADS标准,通过增强CT或MRI检查确诊。将患者分为两组:①通过每6个月超声联合甲胎蛋白(AFP)的结构化监测检出HCC的患者;②在该监测方案之外确诊HCC的患者。主要结局指标为HCC相关死亡。采用Kaplan–Meier法估算总生存期,log-rank检验用于组间生存比较;组间比较根据资料类型分别采用χ²检验、Fisher精确检验、Student t检验或Mann–Whitney U检验。本研究已通过当地伦理委员会批准,所有受试者均签署书面知情同意书。
Methods:Patients from a tertiary HCC referral center were prospectively enrolled between 2019 and 2024. HCC diagnosis was established by contrast-enhanced CT or MRI according to LIRADS criteria. Patients were stratified into: (1) HCC detected through structured surveillance with biannual ultrasound plus alpha-fetoprotein (AFP), and (2) HCC diagnosed outside surveillance protocols. The primary outcome was HCC-related mortality. OS was estimated using the Kaplan–Meier method and compared with the log-rank test. For intergroup comparisons were employed chi-square, Fisher’s exact, Student’s t, or Mann–Whitney U tests, as appropriate. The study was approved by the local Ethics Committee, and all participants provided written informed consent.
结果
本研究共前瞻性纳入206例患者,其中73例(35.4%)于监测过程中确诊HCC,133例(64.6%)在监测方案外确诊HCC。监测组基线AFP水平更低(7.8对比59.0ng/mL,P=0.002),AFP>20ng/mL的患者占比更低(41.1%对比56.9%,P=0.03),早期HCC(BCLC 0/A期)占比更高(71.0%对比35.5%,P<0.001)。监测组肿瘤直径更小(31.5对比54.0mm,P<0.001),ALBI I级占比更高(70.4%对比32.5%,P<0.001),处于肝硬化代偿期的患者占比更高(91.0%对比68.8%,P<0.001)。监测组HCC相关死亡率更低(20.5%对比45.4%,P<0.001),总生存期更长(48.1对比29.7个月,P<0.001)。
Results:A total of 206 patients were prospectively included, of whom 73 (35.4%) were diagnosed under surveillance and 133 (64.6%) outside surveillance protocol. Patients undergoing surveillance had lower baseline AFP levels (7.8 vs. 59.0 ng/mL; p = 0.002), lower prevalence of AFP > 20 ng/mL (41.1% vs. 56.9%; p = 0.03), and higher frequency of early-stage HCC (BCLC 0/A) (71.0% vs. 35.5%; p < 0.001). Surveillance was also associated with smaller tumors (31.5 vs. 54.0 mm; p < 0.001), higher prevalence of ALBI grade I (70.4% vs. 32.5%; p < 0.001), compensated cirrhosis (91.0% vs. 68.8%; p < 0.001), lower HCC-related mortality (20.5% vs. 45.4%; p < 0.001), and longer OS (48.1 vs. 29.7 months; p < 0.001).
结论
结构化HCC监测与更早的确诊分期、更低的肿瘤负荷、更良好的肝储备功能以及更长的总生存相关。上述结果支持在真实世界临床实践中开展HCC监测,有助于提升患者接受根治性治疗的机会,改善长期预后。
Conclusion:HCC surveillance was associated with earlier-stage diagnosis, lower tumor burden, better hepatic reserve, and longer OS. These findings support surveillance as an effective strategy to improve eligibility for curative-intent therapies and optimize long-term outcomes in realworld practice.
二 摘要编号:4265
粪菌移植联合仑伐替尼治疗晚期肝细胞癌:双盲安慰剂对照随机先导试验
FECAL MICROBIOTA TRANSPLANTATION IN ADDITION TO LENVATINIB IN ADVANCED HEPATOCELLULAR CARCINOMA: A DOUBLE-BLIND, PLACEBOCONTROLLED PILOT RANDOMIZED
作者:TRIAL Ayush Agarwal1 Arnav Aggarwal1 Vishal Chauhan1 Shubham Jain1 Sarthak Saxena2 Sejal Kotwani1 Shubham Garg1 Sanchita Gupta1 Shivanand Gamanagatti1 Ankur Goyal1 Raju Sharma1 Bipin Tiwari1 Samagra Agarwal1 Sagnik Biswas1 Shalimar1
1 All India Institute of Medical Sciences, New Delhi
2 All India Institute of Medical Sciences, Delhi
背景
晚期肝细胞癌(HCC)系统治疗的客观缓解率仍偏低。既往研究报道,辅助粪菌移植(FMT)有望改善恶性黑色素瘤患者对免疫治疗的应答。本研究旨在评估FMT联合仑伐替尼治疗晚期HCC的安全性与有效性。
Background:Objective response rates to systemic therapies in advanced hepatocellular carcinoma (HCC) remain low. Adjunctive faecal microbiota transplantation (FMT) has been reported to improve immunotherapy response in malignant melanoma. We aimed to assess the safety and efficacy of FMT in combination with lenvatinib in advanced HCC.
方法
本研究为一项双盲、安慰剂对照的随机先导试验,将初治的BCLC C期晚期HCC成年患者按1∶1比例随机分入FMT组或安慰剂组(等体积生理盐水),两组患者均同步接受按体重给药的口服仑伐替尼治疗。FMT或安慰剂在内镜引导下于仑伐替尼启动治疗前1周输注至十二指肠。FMT菌群来源于2名健康供者,由独立研究人员制备处理。分别于第3个月和第6个月开展影像学、血清学及问卷评估。研究结局包括基于RECIST 1.1标准的肿瘤疗效应答、总生存期(OS)、无进展生存期(PFS)、不良事件以及生活质量(EORTC QLQ-C30与QLQ-HCC18)。
Methods:In this double-blind placebo-controlled pilot randomised trial, treatment naïve adult patients with advanced HCC (Barcelona Clinic Liver Cancer Stage C) were randomly assigned (1:1) to receive either FMT or placebo (equal volume of normal saline), along with systemic therapy with oral weight-based lenvatinib. FMT/placebo instillation in duodenum was done via endoscopy 1 week prior to starting lenvatinib. FMT was sourced from 2 healthy donors and processed by independent research staff. Radiological, serological and questionnaire-based assessments were performed at 3 and 6 months. Outcomes included response (RECIST1.1), overall survival (OS), progression-free survival (PFS), adverse events and quality of life (EORTC QLQ-C30 and QLQ-HCC18) .
结果
本研究共随机入组20例患者,最终19例纳入分析(FMT组9例,安慰剂组10例)。两组基线特征具有可比性:平均年龄56.0±9.5岁,男性占85%;AFP中位数6692(四分位间距1667~25904),平均ALBI评分-2.3±0.1。肝病主要病因是HCV(42.1%)和HBV(36.8%);84.2%的患者合并肝硬化,8例(42.1%)存在肝外转移,15例(78.9%)合并门静脉癌栓。第3个月完成影像学评估的12例患者中,6例(50%)为疾病稳定(两组各3例),其余患者均为疾病进展。至第6个月随访时,FMT组2例维持疾病稳定,安慰剂组2例出现疾病进展(P=0.33)。FMT组与安慰剂组的OS分别为104天(四分位间距84~176)和134天(19~180),P=0.51;PFS分别为100天(84~167)和90天(90~91),P=0.63,组间差异均无统计学意义。两组不良事件发生率相近,包括腹水(总体26.3%)和手足综合征(15.8%)。FMT组发生7例严重不良事件,安慰剂组6例(77.7%对比60%,P=0.6)。治疗第1周,FMT组营养相关症状与疼痛症状评分更低(P分别为0.016和0.029),但两组的总体健康状态及功能量表评分无明显差异。
Results: 20 patients were randomised; 19 were included in analysis (9 in FMT arm, 10 in placebo arm). Baseline characteristics were comparable (mean age: 56.0 ± 9.5 years; 85% males; median AFP 6692 [IQR 1667-25904], mean ALBI score −2.3 ± 0.1). Major etiologies of liver disease were hepatitis C (42.1%) and hepatitis B (36.8%). Cirrhosis was present in 84.2% patients. Extrahepatic metastases were present in 8 (42.1%) patients and portal venous thrombosis in 15 (78.9%) patients. Of 12 patients with radiological assessment at 3 months, 6 (50%) had stable disease (3 per group); the remainder had progressive disease. At 6 months, 2 FMT patients had stable disease and 2 control arm patients had progressive disease (p = 0.33). The OS (104 [IQR 84-176] vs 134 [IQR 19-180] days, p = 0.51) and PFS (100 [IQR 84-167] vs 90 [IQR 90-91] days, p = 0.63) were similar in FMT and control arms. Adverse events, including ascites (26.3%) and hand foot syndrome (15.8%), were similar in both arms. Serious adverse events occurred in 7 patients in FMT arm vs 6 patients in placebo arm (77.7% vs 60%, p = 0.6). Nutritional issues and pain symptom scales were lower in FMT arm at 1 week (p = 0.016 and 0.029 respectively), while global health and functional scale scores were similar in both arms.
结论
对于晚期HCC患者,FMT联合仑伐替尼方案的初步安全性尚可接受。本小样本先导试验并未观察到该方案在肿瘤应答或生存获益方面的明确优势,仍需开展更大样本量的研究加以验证。
Conclusion:Fecal microbiota transplantation in addition to lenvatinib is safe in advanced hepatocellular carcinoma.
三 摘要编号:4360
ALTUS前瞻性多中心研究:MRI LI-RADS 2018分类的阅片者间可重复性
CENTRAL MRI LI-RADS INTER-READER AGREEMENT IN ALTUS, A PROSPECTIVE MULTICENTER HCC SURVEILLANCE STUDY
作者:Alvin Silva1 Binu John2 Mark Camardo3 Amit Singal4 Neehar Parikh5 Ju Dong Yang6 Lewis Roberts7 Paul Elias3 Elle Kielar Grevstad3 Paul Limburg3
1 Department of Radiology, Mayo Clinic, Scottsdale, AZ
2 Division of Gastroenterology and Hepatology, Miami VA Medical Center, Miami, Florida
3 Abbott, Madison, WI
4 University of Texas Southwestern Medical Center, Dallas
5 University of Michigan, Ann Arbor, MI
6 Cedars-Sinai Medical Center, Los Angeles, CA
7 Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota
背景
CT/MRI LI-RADS体系能够实现肝细胞癌(HCC)影像诊断的标准化,但既往绝大多数关于阅片者一致性的研究均为回顾性研究,且采用人工筛选的数据集。本研究基于一项大型前瞻性多中心HCC监测队列的连续横断面影像资料,评估LI-RADS v2018的阅片者间可重复性。
Background:CT/MRI LI-RADS standardizes imaging diagnosis of hepatocellular carcinoma (HCC); however, most inter-reader agreement studies have been retrospective and performed using curated datasets. We report the first inter-reader reproducibility study of LI-RADS v2018 from a large, prospective, multicenter HCC surveillance study utilizing consecutive crosspal imaging examinations.
方法
ALTUS研究(NCT05064553)为美国多中心研究,共纳入2463例肝硬化或慢性HBV感染成人受试者,旨在评估多靶点HCC血液检测的诊断效能,并以中心实验室采用CT/MRI完成的LI-RADSv2018判读作为参照标准。6名接受腹部影像专科培训的放射科医师随机两两配对,在盲态下独立判读1605份MRI检查图像;当判读结果存在分歧时,由另一名高年资腹部放射专科医师进行裁定。研究采用一致比例、Gwet AC2系数及组内相关系数(ICC),评价整体LI-RADS分类、各项核心影像征象、病灶数量及病灶大小的一致性。
Methods:ALTUS (NCT05064553) was a multi-center U.S. study of 2,463 adults with cirrhosis or chronic HBV evaluating the performance of a multi-target HCC blood test with central CT/MRI LI-RADS v2018 assessment as reference. Two blinded, fellowship-trained abdominal radiologists—randomly paired from a pool of six— independently assigned LI-RADS categories to 1,605 MRI exams, with a single, experienced fellowshiptrained radiologist adjudicating any discrepancies.
Inter-reader concordance was evaluated for overall LIRADS classification, individual major features, and observation number and size using percent agreement, Gwet’s AC2, and intraclass correlation coefficient (ICC).
结果
LI-RADS总体分类一致率为75.4%(95% CI:73.2%~77.4%),Gwet AC2为0.90(0.89~0.92),该结果主要得益于LR-Neg阴性病灶(n=1237)高达93.5%(92.0%~94.8%)的一致率。LR-3(n=85)与LR-4(n=20)的一致率偏低,分别仅为22.4%(14.8%~32.3%)和20.0%(8.1%~41.6%)。在LR-3判读不一致的病例中,89.4%(59/66)被另一名阅片者归类为LR-Neg、LR-1或LR-2。在LR-4判读不一致的病例中,31.3%(5/16)被归为LR-3,25.0%(4/16)被判定为恶性类别(LR-5共2例、LR-M共2例)。LR-5(n=25)的一致率为56.0%(33.6%~66.4%);11例判读不一致的LR-5病例中,9.1%(1/11)被归为LR-3,27.3%(3/11)被归为LR-4,9.1%(1/11)被归为LR-M。针对LR-5所需的核心影像征象,动脉期高强化、强化包膜及非周边廓清的一致率依次为68.0%、60.0%和48.0%。病灶计数的一致率仅为15.8%(12.4%~19.8%)。目标病灶大小测量的ICC为0.79,两名阅片者测量值的绝对差值中位数为0.3cm,二者测得的病灶中位大小分别为1.5cm与1.2cm。
Results:Overall LI-RADS concordance was 75.4% (95% CI, 73.2-77.4) with AC2 of 0.90 (0.89-0.92), driven largely by high agreement (93.5%, 92.0-94.8) on LR-Neg (n = 1237) images (Fig. 1). LR-3 (n = 85) and LR-4 (n = 20) concordance was 22.4% (14.8-32.3) and 20.0% (8.1-41.6), respectively. A majority (89.4%, 59/66) of LR-3 discrepancies were LR-Neg, LR-1, or LR-2, whereas 31.3% (5/16) of LR-4 discrepancies were LR-3, and 25.0% (4/16) were malignant (2 LR-5, 2 LR-M). LR-5 (n = 25) concordance was 56.0% (33.6-66.4), with 9.1% (1/11) of discrepancies being LR-3, 27.3% (3/11) LR-4, and 9.1% (1/11) LR-M. LR-5 major feature concordance for arterial phase hyperenhancement, enhancing capsule, and non-peripheral washout were 68.0%, 60.0%, and 48.0%, respectively. Concordance on observation count was 15.8% (12.4-19.8). For index observation size, ICC was 0.79, with a median absolute difference between paired readers of 0.3 cm (median observation size 1.5 vs 1.2 cm).
结论
这项大型前瞻性多中心研究提示,LI-RADS对于阴性MRI检查的阅片一致性较好,但对于判读难度较高的不确定分类,一致性显著降低。这类真实世界中的影像判读差异可能对临床决策产生影响,提示在临床工作与科研实践中,均需强化阅片者同质化培训,并建立带裁定流程的中心影像复核机制。
Conclusion:In this large prospective multicenter cohort, LI-RADS classification demonstrated high agreement in negative examinations, with lower concordance across indeterminate categories where imaging assessment is inherently challenging. Differences in categorization in these settings reflect the complexity of real-world surveillance imaging and may have management implications, underscoring the importance of reader calibration and adjudicated central review in clinical and research settings.
版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
来源:梅斯医学·临床资讯 · news.medsci.cn